DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Bang YJ, Giaccone G, Im SA. et al.
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors.
Ann Oncol 2017;
28: 855-861
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.